Protalix is a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by their proprietary ProCellEx® plant cell-based protein expression system.
The BALANCE study is a clinical research study that will compare the safety and efficacy of an investigational medication ( a potential new medication) with an approved medication, agalsidase beta, also known as Fabrazyme. The investigational medication is a type of medication called enzyme replacement therapy, or ERT. The investigational medication has been designed to help break the body break down the particular fat (lipid molecule) that builds up in the body’s cells because of Fabry disease.
The investigational medication in the BALANCE Study is a new ERT. It is designed to last longer in the body which might help protect the body’s organs from the effects of Fabry disease and reduce symptoms.
Learn more here: http://www.fabrynext.com/
You can also find more information about the BALANCE study, sites and locations at ClinicalTrials.gov